Ultragenyx Pharmaceutical Affirms FY2026 Sales Guidance of $730.000M-$760.000M vs $762.256M Est
Benzinga Newsdesk 1 day ago
NewsGuidance
Ultragenyx Pharmaceutical (NASDAQ:RARE) affirms FY2026 sales outlook from $730.000 million-$760.000 million to $730.000 million-$760.000 million vs $762.256 million estimate.
Ultragenyx Pharmaceutical (NASDAQ:RARE) affirms FY2026 sales outlook from $730.000 million-$760.000 million to $730.000 million-$760.000 million vs $762.256 million estimate.